| 标题 |
945MO AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) |
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of Oncology 作者:Z. Ren; Y. Huang; Y. Guo; M.M. Hou; W. Wang; et al 出版日期:2023 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)